Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05559853 · ClinicalTrials.gov registry record
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
A clinical trial of Brain Metastases and Brain Metastases, Adult, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 119
- Enrollment target
- 1
- Study location
NCT05559853 is a study of Brain Metastases and Brain Metastases, Adult that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 119 participants, below the 211-participant average among 67 other Brain Metastases trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05559853, a study of Brain Metastases and Brain Metastases, Adult, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 119 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST CEST-MRF
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2027-09-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05559853
The ClinicalTrials.gov registry entry for NCT05559853 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 67 other Brain Metastases trials with a reported enrollment target (44% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which CEST-MRF is the first listed.
NCT05559853 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05559853 about?
NCT05559853 is a clinical study titled "Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment". The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therap...
What is the current status of trial NCT05559853?
This trial is currently recruiting. The enrollment target is 119 participants. The study started on 2022-09-22. Estimated completion is 2027-09-22.
What conditions does trial NCT05559853 study?
This clinical trial studies the following conditions: Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer.
What interventions are being tested in trial NCT05559853?
The interventions under investigation include: CEST-MRF (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05559853?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05559853 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.